Nuvectis Pharma Inc (NVCT) - Total Assets
Based on the latest financial reports, Nuvectis Pharma Inc (NVCT) holds total assets worth $35.59 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check cash flow reinvestment rate of Nuvectis Pharma Inc to assess the company's total reinvestment commitment from operating cash flow.
Nuvectis Pharma Inc - Total Assets Trend (2020–2024)
This chart illustrates how Nuvectis Pharma Inc's total assets have evolved over time, based on quarterly financial data. Check Nuvectis Pharma Inc tangible book value ratio to evaluate the tangible quality of the company's equity base.
Nuvectis Pharma Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Nuvectis Pharma Inc's total assets of $35.59 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 99.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Nuvectis Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Nuvectis Pharma Inc worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nuvectis Pharma Inc's current assets represent 100.0% of total assets in 2024, an increase from 87.6% in 2020.
- Cash Position: Cash and equivalents constituted 99.6% of total assets in 2024, up from 86.3% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Nuvectis Pharma Inc Competitors by Total Assets
Key competitors of Nuvectis Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Nuvectis Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.07 | 2.74 | 18.54 |
| Quick Ratio | 3.07 | 2.74 | 18.54 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $24.01 Million | $10.99 Million | $6.83 Million |
Nuvectis Pharma Inc - Advanced Valuation Insights
This section examines the relationship between Nuvectis Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.62 |
| Latest Market Cap to Assets Ratio | 12.44 |
| Asset Growth Rate (YoY) | -3.0% |
| Total Assets | $18.61 Million |
| Market Capitalization | $231.56 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Nuvectis Pharma Inc's assets at a significant premium (12.44x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Nuvectis Pharma Inc's assets decreased by 3.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Nuvectis Pharma Inc (2020–2024)
The table below shows the annual total assets of Nuvectis Pharma Inc from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $18.61 Million | -3.01% |
| 2023-12-31 | $19.18 Million | -5.98% |
| 2022-12-31 | $20.41 Million | +206.52% |
| 2021-12-31 | $6.66 Million | 0.00% |
| 2020-12-31 | $6.66 Million | -- |
About Nuvectis Pharma Inc
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also dev… Read more